← Back to all trials
Completed
NCT02884297
HexafluOride, a Contrast Agent for Placenta Echo-angiography
Conditions: Pregnancy
Sex: Female
Ages: 18 Years – 65 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 55
Sponsor: Centre Hospitalier Régional Metz-Thionville
Location: Chr Metz Thionville Metz
Summary
The purpose of this study is to quantify the placental perfusion during the first trimester of pregnancy by 3D Doppler ultrasound angiography without a contrast agent and by ultrasound with a contrast agent: SonoVue®
Eligibility Criteria
Inclusion Criteria:
* Age ≥18 years and \ 90 mmHg), an uncontrolled systemic hypertension and woman with respiratory distress syndrome
2. Women with risk for IUGR / PE namely:
* Previous history of PE or stunting staff
* Autoimmune disease,
* Chronic Hypertension
* Diabetes
Source: ClinicalTrials.gov (NCT02884297). StuddyBuddy aggregates publicly available trial information.
